1-3 of 3
David Crowe
Close
Sort by
Journal Articles

Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma

Richard J Rickles, Ph.D., Laura Pierce, Thomas Giordano, William Avery, Melissa Farwell, David Crowe, Winnie F. Tam, Ph.D., Mei Chen, Ph.D., Vikram Kansra, PhD, Douglas W. McMillin, BSc, PhD, Kenneth C Anderson, MD, Constantine Mitsiades, M.D., Ph.D., Margaret S. Lee, PhD
Journal: Blood
Blood (2008) 112 (11): 252.
https://doi.org/10.1182/blood.V112.11.252.252
Published: 2008
Journal Articles

Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles, Ph.D., Laura Pierce, Thomas Giordano, Winnie F. Tam, Ph.D., William Avery, Melissa Farwell, David Crowe, Mei Chen, Ph.D., Alexander Brown, Vikram Kansra, PhD, Steffan T. Nawrocki, PhD, Jennifer S Carew, Ph.D., Francis J Giles, MD, Margaret S Lee, PhD
Journal: Blood
Blood (2008) 112 (11): 384.
https://doi.org/10.1182/blood.V112.11.384.384
Published: 2008
Journal Articles

Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions

Douglas W. McMillin, PhD, Richard Rickles, Joseph Negri, Jake Delmore, Melissa G. Ooi, MD, Melissa Farwell, David Crowe, Mei Chen, William Avery, Vikram Kansra, PhD, Kenneth C. Anderson, MD, Margaret S. Lee, PhD, Constantine S. Mitsiades, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2663.
https://doi.org/10.1182/blood.V112.11.2663.2663
Published: 2008